Beyond lymph nodes: 18F-FDG PET/CT in detection of unusual sites of extranodal lymphoma

Background The purpose of this study was to compare between contrast-enhanced computer tomography (CE CT) and 18 F-FDG PET/CT in the detection of extranodal involvement in lymphoma and to correlate between SUV max of the extranodal lesion and the hottest LN. One hundred patients with pathologically...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Egyptian Journal of Radiology and Nuclear Medicine 2019-09, Vol.50 (1), p.29-13, Article 29
Hauptverfasser: Othman, Amal Ibrahim Ahmed, Nasr, Merhan, Abdel-Kawi, Moustafa
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Background The purpose of this study was to compare between contrast-enhanced computer tomography (CE CT) and 18 F-FDG PET/CT in the detection of extranodal involvement in lymphoma and to correlate between SUV max of the extranodal lesion and the hottest LN. One hundred patients with pathologically proven lymphoma underwent whole body 18F-FDG PET/CT and CECT scans. Images were compared regarding the ability of detection of extranodal lymphomatous sites. Kappa agreement was applied to find the degree of agreement between both modalities. Pearson ’ s correlation was used for correlating SUV max of the extranodal lesions and hottest LN. The degree of FDG uptake was correlated with histopathological type. Results There was a poor agreement between PET/CT and CECT in the detection of extranodal sites ( k = 0.32). There was a significant positive moderate correlation between SUV max of the extranodal lesions and hottest LN ( r = 0.45). PET/CT study resulted in up staging of 10% and down staging of 5% of cases. Conclusion In lymphoma staging, FDG PET/CT enables more detection of extranodal involved sites that show normal morphology at CECT. It differentiates lymphomatous infiltration from benign causes of increased FDG uptake with subsequent proper disease staging.
ISSN:2090-4762
0378-603X
2090-4762
DOI:10.1186/s43055-019-0011-1